COVID-19 Vaccines

We currently are administering the SPIKEVAX (Moderna) COVID-19 Vaccine to patients 12 years of age and older. 

Appointments are available for Spikevax now!

 

We are expecting COMIRNATY (Pfizer) soon.

 

COVID-19 vaccines for ages younger than 12 have not yet been approved by the FDA. 

-----------

Per the Update as of September 15, 2023

• Recommendations for use of the 2023–­2024 formulations of Moderna COVID-19 Vaccine and Pfizer-BioNTech COVID-19 Vaccine:

  • Everyone ages 5 years and older is recommended to receive 1 dose of updated (2023–­2024 Formula) mRNA COVID-19 vaccine

  • Children ages 6 months–4 years

    • Initial vaccination: should receive either 2 doses of updated (2023­–2024 Formula) Moderna or 3 doses of updated (2023–­2024 Formula) Pfizer-BioNTech COVID-19 vaccine

    • Received previous mRNA doses: need 1 or 2 doses of updated (2023–­2024 Formula) Moderna or updated (2023­–­2024 Formula) Pfizer-BioNTech COVID-19 vaccine, depending on the number of prior doses

  • People who are moderately or severely immunocompromised

    • Initial vaccination: should receive a 3-dose series of updated (2023–­2024 Formula) Moderna or updated (2023–­2024 Formula) Pfizer-BioNTech COVID-19 vaccine

    • Received previous mRNA doses: need 1 or 2 doses of updated (2023­–2024 Formula) Moderna or updated (2023–­2024 Formula) Pfizer-BioNTech COVID-19 vaccine, depending on the number of prior doses

    • May receive 1 or more additional updated (2023–­­2024 Formula) mRNA COVID-19 vaccine doses

  • Bivalent mRNA COVID-19 vaccines are no longer recommended in the United States

• Updated guidance for COVID-19 vaccination and myocarditis or pericarditis

• Updated guidance for COVID-19 vaccination and Multisystem Inflammatory Syndrome (MIS) in children (MIS-C) and in adults (MIS-A)

• Reorganization and consolidation of sections on contraindications and precautions, including allergic reactions to COVID-19 vaccines

​

Per the Update from the CDC on April 22, 2023

• People ages 65 years and older or those who are moderately or severely immunocompromised may receive one additional dose of the Bivalent vaccine, at least 4 months after their last Bivalent dose 

• People ages 6 years and older who are unvaccinated or previously received only monovalent vaccine doses are recommended to receive 1 Bivalent mRNA vaccine dose

• Children who are ages 6 months to 5 years are now recommended to receive at least one dose of Bivalent vaccine (or more) depending on vaccine of choice and vaccines previously received.

• Monovalent mRNA vaccines (e.g., Spikevax, Comirnaty, etc.) are no longer available or offered for vaccination for all age groups.